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Abstract
Background: Ultrastructural and biochemical abnormalities of mitochondria have been reported
in skeletal muscle biopsies of CADASIL patients with mutations in the NOTCH3 nuclear gene.
Additionally, it was proposed that NOTCH3 gene mutations may predispose the mitochondrial
DNA (mtDNA) to mutations.
Methods: We sequenced the entire mitochondrial genome in five Arab patients affected by
CADASIL.
Results: The mean number of mtDNA sequence variants (synonymous and nonsynonymous) in
CADASIL patients was not statistically significantly different from that in controls (p = 0.378). After
excluding haplogroup specific single nucleotide polymorphisms (SNPs) and proved silent
polymorphisms, no known or novel pathologic mtDNA mutation(s) could be detected in any
patient. Additionally, there was no difference in the prevalence of different mitochondrial
haplogroups between patients and controls.
Conclusion: Our study group is too small for any valid conclusion to be made. However, if our
observation is confirmed in larger study group, then mtDNA mutations or mitochondrial
haplogroups may not be important in the pathogenesis of CADASIL.
Background
Cerebral autosomal dominant arteriopathy with subcorti-
cal infarcts and leukoencephalopathy (CADASIL) (MIM
125310) is characterized by degeneration of vascular
smooth muscle cells (VSMC) of nearly all tissues studied
to date. The disease is caused by mutations of the
NOTCH3  gene encoding the transmembrane receptor
NOTCH3, which is expressed predominantly in VSMC
[1]. Electron microscopic examination of muscle and
nerve biopsies from CADASIL patients with NOTCH3
mutations revealed enlarged mitochondria with needle-
like calcium precipitates [2]. A muscle biopsy and brain
magnetic resonance spectroscopic imaging, for a
CADASIL patient with frameshift deletion in the
NOTCH3 gene, showed signs of mitochondrial impair-
ment (ultrastructural mitochondrial abnormalities and
increased parenchymal brain lactate respectively) [3].
Ultrastructural examination of Fibroblasts and myobalsts
from a CADASIL patient revealed mitochondrial aberra-
tion and reduced numbers. The patient harbors a
NOTCH3 mutation and a mitochondrial mutation (5650
G> A) in the tRNA (Ala) gene [4]. Finnila et al. assumed
that the co-occurrence of the two mutations is not coinci-
dental and that mutations in the NOTCH3 gene may pre-
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dispose the mtDNA to mutations [4]. Sequencing the
entire mtDNA coding region in 77 CADASIL patients and
192 matching controls revealed the presence of higher
number of polymorphisms among patients in compari-
son to controls [5]. A significant decrease in the activity of
complex I was noted in a muscle biopsy taken from a
Spanish CADSAIL patient and histochemical analysis of
his affected family members showed the presence of rag-
ged-red fibers with abnormal cytochrome c oxidase stain-
ing [6]. Dotti and others looked for common pathogenic
mtDNA mutations in DNA extracted from the skeletal
muscles of one CADASIL patient, and detected none [3].
Muscle biopsies were not available to us, but given that
mitochondrial dysfunctions can now be detected in circu-
lating leukocytes of patients with various mitochondrial
disorders [7-10], we sequenced the full mitochondrial
genome from DNA extracted from circulating leukocytes
of five CADASIL patients in order to search for any patho-
genic mtDNA mutation.
Methods
Patient's enrollment
Requests to identify cases and participants in this study
was done through mailing a brief Inclusion Criteria form
(see below) for the disease to all members of the Pan Arab
Union of Neurological Sciences (PAUNS). Families were
included when an index case had both a history of tran-
sient ischemic attacks (TIA) or subcortical stroke of uni-
dentified etiology, positive family history of stroke with
early death or dementia compatible with autosomal dom-
inant traits, and a cranial MRI scan showing diffuse or
focal microangiopathic white matter abnormalities. Five
patients (Figure-1) with pure ethnic backgrounds fulfilled
the inclusion criteria for CADASIL. Patient (1) and (2)
were from Saudi Arabia, patient (3) was from Kuwait,
patient (4) was from Sudan and finally, patient (5) was
from Yemen.
Controls enrollment
Control subjects included: 1) 159 Saudi Arabian blood
donors at the King Faisal Specialist Hospital and Research
Centre who represented the spectrum of the Saudi popu-
lation; 2) 50 healthy Sudanese individuals; 3) 57 Egyp-
tians; 4) 108 healthy individuals from Yemen and 5) 120
individuals from gulf countries (Oman, Qatar, Kuwait
and Bahrain). All Arab subjects in our repository reported
no symptomatic metabolic, genetic, ocular or neurologi-
cal disorders on an extensive questionnaire regarding fam-
ily history, past medical problems and current health.
Sample collection and DNA extraction
Ten ml of peripheral blood were collected in EDTA tubes
from all participating individuals after obtaining their
written informed consent approved by the KFSH-IRB.
DNA was extracted from whole blood samples of all
CADASIL patients and controls using the PUREGENE
DNA isolation kit from Gentra Systems (Minneapolis,
USA).
mtDNA amplification and sequencing
The entire mitochondrial genome was amplified in all
patients and controls using primers and amplification
conditions described previously [11]. Each successfully
amplified fragment was directly sequenced using the same
primers used for amplification and the BigDye Terminator
V3.1 Cycle Sequencing kit (Applied Biosystems, Foster
City, CA). Samples were run on the ABI prism 3100
sequencer (Applied Biosystems).
Sequence analysis of the mitochondrial DNA genome
The full mitochondrial genome was sequenced. Sequenc-
ing results were compared to the corrected Cambridge ref-
erence sequence [12]. All fragments were sequenced in
both forward and reverse directions at least twice for con-
firmation of any detected variant. All sequence variants
from both CADASIL patients and controls were compared
to the Mitomap database [13], the Human Mitochondrial
Genome Database [14], GenBank [15], and Medline listed
publications. Reported homoplasmic synonymous or
non-synonymous (NS; resulting in amino acid change)
polymorphisms used predominantly for haplogroup
analysis were excluded from further consideration [16].
Prediction of pathogenicity
Pathologic characteristics of each NS sequence change, in
both CADASIL patients and controls, were estimated
according to a combination of standard pathogenicity cri-
teria [17] and an evaluation of interspecies conservation
using the PolyPhen database [18]. Therefore, a NS nucle-
otide change was considered potentially pathologic, if it
met all of the following criteria, when applicable: 1) it was
not found in at least 100 controls of matching ethnicity;
2) it changed a moderately or highly conserved amino
acid; 3) it was assessed as possibly or probably pathologic
by PolyPhen; 4) it was not established as one of the hap-
logroup-specific SNPs and 5) It was not reported as an
established polymorphism in MITOMAP database, the
Human Mitochondrial Genome Database, GenBank, and
Medline listed publications.
Results
Clinical findings and NOTCH3  mutation detected in
these CADASIL patients have been described previously
[19]
Here, we sequenced the full mtDNA genome in five
CADASIL patients and 159 ethnicity matching controls.
The mean number of sequence changes, relative to the
Cambridge reference sequence, detected in CADASIL
patients (n = 5) was 18 SD 0.707 and among healthy con-BMC Research Notes 2008, 1:16 http://www.biomedcentral.com/1756-0500/1/16
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trols (n = 159) was 17.4 SD 1.51. The difference between
the two groups was not statistically significant (p = 0.378).
All D-loop variants detected in CADASIL patients were
also present in controls.
Table 1 details the five non-synonymous mtDNA
sequence changes found in CADASIL patients after
excluding all synonymous mtDNA changes, established
non-synonymous polymorphisms, and non-synonymous
mtDNA sequence changes relevant primarily to haplo-
group designation. None of these non-synonymous
mtDNA sequence changes were novel (not previously
reported) and all were not present in ethnicity-matched
healthy controls (n = 159). Three of the five non-synony-
Family Pedigrees Figure 1
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mous sequence variants were transversions and the
remaining two were transitions. All were homoplasmic
and applying the pathogenicity prediction criteria
detailed in methods, none of these non-synonymous
sequence changes were potentially pathologic.
Table 2 details the NOTCH3 mutation in each patient and
the non-synonymous mtDNA sequence changes detected
in each patient. Four CADASIL patients had NOTCH3
mutation and one patient from the Sudan had none after
sequencing the full NOTCH3 gene. None of the CADASIL
patients had any potentially pathological mtDNA
sequence. Additionally, we classify the CADASIL patients
into their respective mitochondrial haplogroup. Each
patient belonged to a unique mitochondrial haplogroup
(Table 2). All
Discussion
We have previously described five Arab patients belonging
to five unrelated pedigrees with a clinical phenotype typi-
cal of CADASIL. NOTCH3 mutations were found in four
of those and we concluded that CADASIL occurs in Arabs,
with clinical phenotype and genotype similar to that in
other ethnic groups [19]. As there has been considerable
increase in the number of studies demonstrating mito-
chondrial abnormalities in CADASIL patients, we
sequenced the entire mitochondrial genome with aim of
detecting established or potentially pathogenic mtDNA
sequence changes. One study has shown a higher number
of mtDNA-polymorphisms among CADASIL patients in
comparison to healthy controls and detected three patho-
genic mtDNA mutations in three separate CADASIL pedi-
grees [5]. However, this was not the case in our study as
the number of polymorphisms was similar in both
patients and controls. Additionally, we could not detect
any pathogenic mtDNA mutation among our study
group. The differences in mtDNA-polymorphisms
observed in their study could be as a result of differences
in haplogroup frequencies between CADASIL patients
and controls as was stated [5]. Only 3/77 (3.9%) of their
CADASIL pedigrees had pathogenic mtDNA mutations
and therefore, this finding cannot be taken as a complete
picture. In light of our findings and others [4-6], previous
hypothesis that NOTCH3 contribution to mtDNA main-
tenance and that, mutations in NOTCH3 increase the fre-
quency of mutations in mtDNA [4] may not be
compelling enough. Additionally, our CADSIL patients
were assigned into their respective mitochondrial haplo-
Table 2: Summary of the NOTCH3 mutations and mitochondrial abnormalities detected in CADASIL patients
Patient Ethnicit
y
Notch3mutation 
detected
NS+ mtDNA 
sequence changes
Mitochondrial haplogroup 
Of CADASIL patients
Percentage  of mitochondrial 
haplogroup in controls (n = 552)
1 Saudi c.406 C> T 14113 M 3.1%
2 Saudi c.1568 C> T 3851 K 4%
3 Kuwait c.406 C> T 14171 N 7.4%
4 Sudan ND 15048 preHV1 17.9%
5 Yemen c.475 C> T 14966 J 21%
ND = not detected
+ All non-synonymous (NS) mtDNA sequence changes reported above were not detected in 159 matching healthy controls.
  Percentage of Mitochondrial haplogroups among 552 healthy Arabs as previously reported by Abu-Amero et al., 2008 [20]
Table 1: Non-synonymous mtDNA sequence changes detected in CADASIL patients
Nucleotide 
substitution
Amino Acid 
substitution
Base 
substitution 
type
Location Hetero-
plasmy (%)
Interspecies 
conservation
PolyPhen 
prediction
Pathogenicity 
prediction
3851 C>G A182G Transversion TM domain of ND1 gene N/A Moderate Benign Non-pathologic
14113 T>C F593L Transition TM domain of ND5 gene N/A Low Benign Non-pathologic
14171 A>G I168T Transition TM domain of ND6 gene N/A Low Benign Non-pathologic
14966 A>C N74H Transversion Outside the functional 
domain of CYTB gene
N/A High Benign Non-pathologic
15048 G>C G101A Transversion Outside the functional 
domain of CYTB gene
N/A Moderate Benign Non-pathologic
Base substitution type – Transversion = A mutation in which a purine/pyrimidine replaces a pyrimidine/purine base pair or vice versa [G:C > 
T:A or C:G, or A:T > T:A or C:G]; Transition = A mutation in which a purine/pyrimidine base pair is replaced with a base pair in the same purine/
pyrimidine relationship [A:T > G:C or C:G > T:A]. Interspecies conservation was assessed using PolyPhen [21] which determines interspecies 
conservation for an altered amino acid by performing alignment with all available amino acid sequences for other species. Pathogenicity 
prediction = A sequence variant was considered potentially pathogenic if it satisfied all the condition detailed in methods. None of above listed 
non-synonymous sequence changes were found in ethnicity-matched controls (n = 159).Publish with BioMed Central    and   every 
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group. Each patient had a unique haplogroup and those
were also present in Arab healthy population [20]. We
could not calculate the statistical significant differences in
the mitochondrial haplogroup frequencies between con-
trols and patients due to the fact that each patient had a
unique haplogroup. Consequently, the number was too
small to make a statistical comparison and as a result we
could not reach a conclusion whether mitochondrial hap-
logroup is a risk factor for CADASIL or not. However, if
our observation is confirmed in larger study group, then
mtDNA mutations or mitochondrial haplogroups may
not be important in the pathogenesis of CADASIL. This
does not exclude the fact that other mitochondrial abnor-
malities, such as alteration in mitochondrial respiration
or ultra-structure, could be involved.
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